Eli Lilly Canada Inc., Toronto, ON, CanadaFaculty of Medicine, Discipline of Psychiatry, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, CanadaEli Lilly and Company, Indianapolis, IN, USADepartment of Medicine, Faculty of Medicine, University of Toronto and St. Michael's Hospital, Toronto, ON, CanadaDepartment of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The NetherlandsDepartment of Psychiatry, University of California, Irvine, CA, USADepartment of Psychiatry, Queen's University, Kingston, ON, CanadaIntercontinental Information Sciences, Eli Lilly Australia Pty. Limited, Macquarie Park, NSW, Australia.
Int J Clin Pract. 2010 Oct;64(11):1520-1529. doi: 10.1111/j.1742-1241.2010.02485.x.
We conducted exploratory analyses of the data from a multinational, randomised study to identify factors associated with weight change after 16 weeks of treatment with standard olanzapine tablets (SOT) or sublingual orally disintegrating olanzapine (ODO).
One hundred and forty nine outpatients who gained weight during prior SOT therapy were enrolled into the study and treated with ODO (N = 84) or SOT (N = 65). Exploratory analyses were conducted with the subset of compliant patients (ODO: n = 60; SOT: n = 47).
The decrease in the rate of weight gain at the end of study therapy (change from baseline) was greater in the ODO group than the SOT group (-0.59 kg/week vs. -0.38 kg/week, p = 0.0246). Age was negatively associated with weight change (p = 0.0203) in both treatment groups combined: patients gained 0.7 kg less for every 10 years of age. The least squares mean weight gain was lower with ODO than SOT in male patients (0.35 kg vs. 3.04 kg, p = 0.061), but not female patients and in American patients (0.55 kg vs. 6.21 kg, p < 0.0001), but not Canadian or Mexican patients.
Although not conclusive, these data suggest that ODO may be a reasonable treatment option for some patients who gain weight with SOT. Further research is required to confirm these findings.
我们对一项多中心、随机研究的数据进行了探索性分析，以确定与标准奥氮平片（SOT）或舌下速溶奥氮平（ODO）治疗 16 周后体重变化相关的因素。
149 名在先前 SOT 治疗期间体重增加的门诊患者被纳入该研究，并接受 ODO（N=84）或 SOT（N=65）治疗。对符合条件的患者亚组（ODO：n=60；SOT：n=47）进行了探索性分析。
研究治疗结束时体重增加率的下降在 ODO 组比 SOT 组更大（从基线的变化-0.59kg/周 vs.-0.38kg/周，p=0.0246）。年龄与两组联合治疗的体重变化呈负相关（p=0.0203）：每增加 10 岁，患者体重就会减少 0.7 公斤。ODO 组男性患者的体重增加低于 SOT 组（0.35kg vs.3.04kg，p=0.061），而女性患者和美国患者的体重增加则高于 SOT 组（0.55kg vs.6.21kg，p<0.0001），但加拿大或墨西哥患者则不然。
尽管这些数据尚不能得出结论，但它们表明 ODO 可能是一些因 SOT 而体重增加的患者的合理治疗选择。需要进一步研究来证实这些发现。
